Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
8Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Altimmune, Inc. (ALT) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
14Total relationships
4Distinct source URLs
6High confidence
0.757Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Altimmune, Inc. Suppliers
Ticker
Name
Confidence
Evidence
MEDERIS-DIABETES-LLC
MEDERIS-DIABETES-LLC
92%
Pursuant to a license agreement between the Company and Mederis Diabetes, LLC ("Mederis") (the "Mederis IP License Agreement"), we are the exclusive licensee of patent rights owned by Mederis to deve…
TITAN-PARTNERS-GROUP-LLC
TITAN-PARTNERS-GROUP-LLC
92%
The Company also entered into a Placement Agency Agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC
Reciprocal relationship from HTGC graph: Reciprocal relationship from ALT graph: h expected cash receipts from our equity transactions and research and development incentives, are sufficient to fund …
h expected cash receipts from our equity transactions and research and development incentives, are sufficient to fund operations for at least a twelve-month period from the issuance date of our Decem…
B-RILEY-SECURITIES-INC
B-RILEY-SECURITIES-INC
62%
ipts from our equity transactions and research and development incentives, are sufficient to fund operations for at least a twelve-month period from the issuance date of our December 31, 2024 consoli…
COMPANY-INCORPORATED
COMPANY-INCORPORATED
62%
h expected cash receipts from our equity transactions and research and development incentives, are sufficient to fund operations for at least a twelve-month period from the issuance date of our Decem…
EVERCORE-GROUP-L-L-C-JMP-SECURITIES-LLC
EVERCORE-GROUP-L-L-C-JMP-SECURITIES-LLC
62%
ipts from our equity transactions and research and development incentives, are sufficient to fund operations for at least a twelve-month period from the issuance date of our December 31, 2024 consoli…
LEERINK-PARTNERS-LLC
LEERINK-PARTNERS-LLC
62%
h expected cash receipts from our equity transactions and research and development incentives, are sufficient to fund operations for at least a twelve-month period from the issuance date of our Decem…
ORGANIZATION-ALTIMMUNE-INC
ORGANIZATION-ALTIMMUNE-INC
62%
inancial statements, material advance payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as exp…
SPITFIRE-PHARMA-INC
SPITFIRE-PHARMA-INC
62%
ed from Spitfire Pharma, Inc. (the “Sales Milestone”) within ten years following the approval of a new drug application filed with the U.S. Food and Drug Administration (the “FDA”). The contingent pa…
Altimmune, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ALT-DEBT
Debt stack $34.7M
90%
Market cache reports total debt of $34.7M.
ALT-DEBT-7697
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2017-12-31.
ALT-DEBT-7696
Warrants outstanding: 1593753
90%
xbrl warrant detail from xbrl 2024-12-31.
Altimmune, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Altimmune, Inc..
Altimmune, Inc. Ownership
Holder
Name
Confidence
Evidence
ALT-OWNER-BLACKROCK-INC
BlackRock, Inc.
90%
13F overlay lists BlackRock, Inc. as top holder; 176 tracked holders.
